Mark Takata

Scripps Clinic Medical Group

Papers

1

Total Citations

14

H-Index

1

About

Dr. Mark Takata is a leading clinical researcher in hernia surgery and surgical outcomes, with a focused expertise in the evaluation of novel biologic and synthetic mesh technologies for abdominal wall reconstruction. His most cited work, the 24-month results of the BRAVO study, represents a landmark prospective, multi-center clinical trial (NCT03074474) assessing the OviTex® 1S reinforced tissue matrix for ventral hernia repair. This pivotal study, which tracked a 92-patient cohort, provided critical long-term evidence on the durability and safety of this permanent reinforced scaffold, demonstrating low recurrence rates and favorable complication profiles. With over 14 citations, the BRAVO study has become a foundational reference for surgeons evaluating advanced mesh options. Dr. Takata’s research directly addresses the pressing clinical challenge of optimizing outcomes in complex hernia patients, bridging the gap between preclinical innovation and real-world surgical practice. His work is essential reading for any resident or fellow seeking to understand the evidence behind modern hernia repair techniques and the rigorous clinical data required to validate new biomaterials in high-stakes abdominal wall surgery.

Research Focus

Key Achievements

1
H-Index
1
Papers
14
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
24-Month results of the BRAVO study: A prospective, multi-center study evaluating the clinical outcomes of a ventral hernia cohort treated with OviTex® 1S permanent reinforced tissue matrix
14 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 7
🏛 Institutions: Scripps Clinic Medical Group

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago